Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aura Biosciences (AURA) Preferred Stock Liabilities (2020 - 2021)

Aura Biosciences filings provide 2 years of Preferred Stock Liabilities readings, the most recent being $29.4 million for Q3 2021.

  • Quarterly Preferred Stock Liabilities fell 28.58% to $29.4 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $29.4 million through Sep 2021, down 28.58% year-over-year, with the annual reading at $128.1 million for FY2020, N/A changed from the prior year.
  • Preferred Stock Liabilities hit $29.4 million in Q3 2021 for Aura Biosciences, up from $3.4 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $128.1 million in Q4 2020 and bottomed at $3.4 million in Q2 2021.